WARSAW, Poland, August 7 /PRNewswire/ --

- Changes Will Further Enhance Client Services and Capabilities at Central Europe's Largest Commercial Printer

- Polish Operations to be Rebranded QuadWinkowski

To better serve magazine publishers, catalogers and retailers throughout Poland and Europe, U.S.-based Quad/Graphics and Poland-based Winkowski have augmented company leadership and committed to capital investments totaling 35 million USD (72 million PLN) at Winkowski.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080806/AQW513LOGO)

Further, now that Quad/Graphics has a majority ownership in Winkowski (since December 2007), the company will be rebranded QuadWinkowski to reflect the combined resources of the two companies.

DALLAS, August 7 /PRNewswire/ --

- CONNECTIONS(TM) Europe Summit focuses on entertainment and multimedia services in European markets

Rapid growth in home networking, approaching 168 million households worldwide in 2008, is laying the foundation for expansion of multimedia services internationally and especially in the European markets, according to Parks Associates.

The market research firm will host CONNECTIONS(TM) Europe Summit on August 29, 2008, at the Kempinski Hotel Bristol Berlin, to discuss the implications of this market growth and share the latest findings of its Global Digital Living(TM) (GDL) project.

CHICAGO, August 7 /PRNewswire/ --

Townsend Analytics (http://www.townsendanalytics.com), a leading provider of global multi-broker, cross-asset electronic trading solutions, today announced its connection to Morgan Stanley's Electronic Trading (MSET) platform. The arrangement allows clients to access MSET services through Townsend Analytics' flagship EMS, RealTick(R).

KIRKLAND, Washington, August 7 /PRNewswire/ --

ProteoTech Inc. (ProteoTech) today announced that it has completed regulatory Investigational New Drug (IND) requirements and has been cleared by the FDA to initiate its Phase 1 human clinical trial on Exebryl-1(R), a novel small molecule drug targeting toxic beta-amyloid protein accumulation for the treatment of Alzheimer's disease. ProteoTech initiated its Phase 1 human trial on July 29, 2008.

BRITISH COLUMBIA, Canada, August 7 /PRNewswire/ --

InNexus Biotechnology Inc., (TSX: IXS.V; OTC Bulletin Board: IXSBF) (http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, announced today that it has launched a large scale primate study of DXL625 (CD20), the company's lead program.

ISTANBUL, Turkey, August 7 /PRNewswire/ --

- Company Announces Joint Venture Partnership with Turkey's leading Media Group

Brightstar Corp., a global leader in customized distribution and integrated supply chain solutions for the wireless industry, announced today its entrance into Turkey. The addition of Turkey marks Brightstar's further entrance into Eastern Europe, and enhances the company's global geographic leadership in more than 50 countries on six continents.